Search Results - "RICHMAN, D. D"

Refine Results
  1. 1

    Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy by Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., Richman, D. D., Hudgens, M. G., Bosch, R. J., Coffin, J. M., Eron, J. J., Hazuda, D. J., Margolis, D. M.

    Published in Nature (London) (26-07-2012)
    “…The latent HIV-1 reservoir represents a major barrier to curing patients with HIV-1 infection, and now in vivo evidence is presented that vorinostat can…”
    Get full text
    Journal Article
  2. 2

    Highly precise measurement of HIV DNA by droplet digital PCR by Strain, Matthew C, Lada, Steven M, Luong, Tiffany, Rought, Steffney E, Gianella, Sara, Terry, Valeri H, Spina, Celsa A, Woelk, Christopher H, Richman, Douglas D

    Published in PloS one (03-04-2013)
    “…Deoxyribonucleic acid (DNA) of the human immunodeficiency virus (HIV) provides the most sensitive measurement of residual infection in patients on effective…”
    Get full text
    Journal Article
  3. 3

    HIV chemotherapy by Richman, Douglas D

    Published in Nature (London) (19-04-2001)
    “…The use of chemotherapy to suppress replication of the human immunodeficiency virus (HIV) has transformed the face of AIDS in the developed world. Pronounced…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Antiviral Drug Discovery To Address the COVID-19 Pandemic by Richman, Douglas D

    Published in mBio (25-09-2020)
    “…The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery…”
    Get full text
    Journal Article
  6. 6

    HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy by Honeycutt, Jenna B, Thayer, William O, Baker, Caroline E, Ribeiro, Ruy M, Lada, Steven M, Cao, Youfang, Cleary, Rachel A, Hudgens, Michael G, Richman, Douglas D, Garcia, J Victor

    Published in Nature medicine (01-05-2017)
    “…Persistence of HIV is attributed primarily to latent infection of CD4 + T cells. Honeycutt et al . report that in humanized mice lacking T cells HIV can…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Rapid Evolution of the Neutralizing Antibody Response to HIV Type 1 Infection by Richman, Douglas D., Wrin, Terri, Little, Susan J., Petropoulos, Christos J.

    “…A recombinant virus assay was used to characterize in detail neutralizing antibody responses directed at circulating autologous HIV in plasma. Examining serial…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Challenge of Finding a Cure for HIV Infection by Richman, Douglas D, Margolis, David M, Delaney, Martin, Greene, Warner C, Hazuda, Daria, Pomerantz, Roger J

    “…Although combination therapy for HIV infection represents a triumph for modern medicine, chronic suppressive therapy is required to contain persistent…”
    Get full text
    Journal Article
  12. 12

    Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review by Stadeli, Kathryn M, Richman, Douglas D

    Published in Antiviral therapy (01-01-2013)
    “…The increasing availability of antiretroviral therapy (ART) has improved survival and quality of life for many infected with HIV, but can also engender drug…”
    Get more information
    Journal Article
  13. 13
  14. 14

    Lipoprotein-like receptor 4 antibodies in myasthenia gravis: pathogenic or protective by Richman, D. P.

    Published in European journal of neurology (01-11-2016)
    “…Click here to view the accompanying paper in this issue…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis by SANDERS, D. B, HART, I. K, MANTEGAZZA, R, SHUKLA, S. S, SIDDIQI, Z. A, DE BAETS, M. H. V, MELMS, A, NICOLLE, M. W, SOLOMONS, N, RICHMAN, D. P

    Published in Neurology (05-08-2008)
    “…This prospective, randomized, double-blind, placebo-controlled, phase III trial assessed the efficacy, safety, and tolerability of mycophenolate mofetil (MMF)…”
    Get full text
    Journal Article
  18. 18

    The prevalence of antiretroviral drug resistance in the United States by RICHMAN, Douglas D, MORTON, Sally C, WRIN, Terri, HELLMANN, Nicholas, BERRY, Sandra, SHAPIRO, Martin F, BOZZETTE, Samuel A

    Published in AIDS (London) (02-07-2004)
    “…Antiretroviral therapy has dramatically reduced the morbidity and mortality of infection due to HIV. The emergence of drug-resistant virus has limited the…”
    Get full text
    Journal Article
  19. 19
  20. 20